Executive Severance Benefits Agreement Sample Contracts

Executive Severance Benefits Agreement (October 12th, 2018)
Amended and Restated Executive Severance Benefits Agreement (August 3rd, 2018)

This AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the "Agreement") is entered into effective as of this [ ] day of [ ], 2018 (the "Effective Date"), between [ ] ("Executive") and MELLANOX TECHNOLOGIES, LTD. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events and supersedes in its entirety any prior Executive Severance Benefits Agreement entered into by and between Executive and the Company (the "Prior Agreement"). Certain capitalized terms used in this Agreement are defined in Article 5.

Amended and Restated Executive Severance Benefits Agreement (August 3rd, 2018)

This AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the "Agreement") is entered into effective as of this [ ] day of [ ] (the "Effective Date"), between [ ] ("Executive") and MELLANOX TECHNOLOGIES, LTD. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events and supersedes in its entirety any prior Executive Severance Benefits Agreement entered into by and between Executive and the Company (the "Prior Agreement"). Certain capitalized terms used in this Agreement are defined in Article 5.

Executive Severance Benefits Agreement (March 9th, 2018)

This Executive Severance Benefits Agreement (the "Agreement") is entered into this 30th day of November, 2017 (the "Effective Date") between William P. Quinn ("Executive") and Sunesis Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.

Executive Severance Benefits Agreement (February 27th, 2018)

This Executive Severance Benefits Agreement (this "Agreement"), effective as of March 20, 2017 (the "Effective Date"), is between Helen Collins ("Executive") and Five Prime Therapeutics, Inc. ("FivePrime"). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Amendment No. 2 to the Executive Severance Benefits Agreement (November 6th, 2017)

This Amendment No. 2 to the Executive Severance Benefits Agreement (this "Amendment"), effective January 1, 2018 (the "Amendment Effective Date"), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime"), and Aron Knickerbocker, an individual ("Executive").

Amendment No. 1 to the Executive Severance Benefits Agreement (February 24th, 2017)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this "Amendment"), effective January 21, 2016 (the "Amendment Effective Date"), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime"), and Robert Sikorski, an individual ("Executive").

Executive Severance Benefits Agreement (February 24th, 2017)

This Executive Severance Benefits Agreement (this "Agreement") is entered into as of 9.17.2014 (the "Effective Date"), between Robert Sikorski, an individual ("Executive") and Five Prime Therapeutics, Inc. ("FivePrime"). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement (February 24th, 2017)

This Executive Severance Benefits Agreement (this "Agreement"), effective as of February 1, 2016 (the "Effective Date"), between Kevin Paul Baker, Ph.D. ("Executive") and Five Prime Therapeutics, Inc. ("FivePrime"). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Third Amended and Restated Executive Severance Benefits Agreement (May 9th, 2016)

This Third Amended and Restated Executive Severance Benefits Agreement (the "Agreement") is entered into this 13th day of April, 2016 (the "Effective Date"), between Eric H. Bjerkholt ("Executive") and Sunesis Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.

Third Amended and Restated Executive Severance Benefits Agreement (May 9th, 2016)

This Third Amended and Restated Executive Severance Benefits Agreement (the "Agreement") is entered into this 13th day of April, 2016 (the "Effective Date"), between Daniel N. Swisher, Jr. ("Executive") and Sunesis Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement (August 6th, 2014)

This Executive Severance Benefits Agreement (the "Agreement") is entered into as of June 27, 2014 (the "Effective Date"), between EMPLOYEE, ("Executive") and Portola Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 5.

Executive Severance Benefits Agreement (July 2nd, 2014)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of June 27, 2014 (the Effective Date), between EMPLOYEE, (Executive) and PORTOLA PHARMACEUTICALS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 5.

Executive Severance Benefits Agreement (March 6th, 2014)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into this 6th day of March, 2014 (the Effective Date), between JOSEPH DEPINTO (Executive) and SUNESIS PHARMACEUTICALS, INC. This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.

Amendment No. 1 to the Executive Severance Benefits Agreement (January 22nd, 2014)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this Amendment), effective January 16, 2014 (the Amendment Effective Date), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (FivePrime), and Marc Belsky, an individual (Executive).

Executive Severance Benefits Agreement (January 22nd, 2014)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 3rd day of December, 2012 (the Effective Date), between JULIE HAMBLETON, MD, . (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement (January 22nd, 2014)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 30th day of December, 2009 (the Effective Date), between MARC L. BELSKY (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement for Executive Vice Presidents and Senior Vice Presidents1 (December 9th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the day of , 2013, and shall be effective as of the closing date of and subject to the consummation of the Transaction (as defined below), by and among (Executive), American Airlines, Inc., a Delaware corporation (including any successor, American), and AMR Corporation, a Delaware corporation (AMR).

2007 Executive Severance Benefits Agreement (July 26th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 19th day of April, 2007 (the Effective Date), between LEWIS T (RUSTY) WILLIAMS (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Amendment No. 1 to the Executive Severance Benefits Agreement (July 26th, 2013)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this Amendment), effective May 8, 2013 (the Amendment Effective Date), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (FivePrime), and Francis Sarena, an individual (Executive).

Amendment No. 1 to the Executive Severance Benefits Agreement (July 26th, 2013)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this Amendment), effective December 5, 2012 (the Amendment Effective Date), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (FivePrime), and Aron Knickerbocker, an individual (Executive).

Executive Severance Benefits Agreement (July 26th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 30th day of December, 2009 (the Effective Date), between ARON M. KNICKERBOCKER (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement (July 26th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 18th day of February, 2011 (the Effective Date), between FRANCIS SARENA, J.D., (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

2007 Executive Severance Benefits Agreement (June 14th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 19th day of April, 2007 (the Effective Date), between LEWIS T (RUSTY) WILLIAMS (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Amendment No. 1 to the Executive Severance Benefits Agreement (June 14th, 2013)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this Amendment), effective May 8, 2013 (the Amendment Effective Date), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (FivePrime), and Francis Sarena, an individual (Executive).

Executive Severance Benefits Agreement (June 14th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 18th day of February, 2011 (the Effective Date), between FRANCIS SARENA, J.D., (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Amendment No. 1 to the Executive Severance Benefits Agreement (June 14th, 2013)

This Amendment No. 1 to the Executive Severance Benefits Agreement (this Amendment), effective December 5, 2012 (the Amendment Effective Date), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (FivePrime), and Aron Knickerbocker, an individual (Executive).

Executive Severance Benefits Agreement (June 14th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into as of the 30th day of December, 2009 (the Effective Date), between ARON M. KNICKERBOCKER (Executive) and FIVE PRIME THERAPEUTICS, INC. (the Company). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.

Executive Severance Benefits Agreement (March 26th, 2013)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is made and entered into effective as of April 28, 2010 (the Commencement Date), between Guitar Center, Inc., a Delaware corporation (the Company), and Eugene J. Joly (the Executive).

Sunesis Pharmaceuticals, Inc. Amendment to Executive Severance Benefits Agreement (March 13th, 2013)

THIS AMENDMENT TO EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Amendment) is made as of October 24, 2012, by and between SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the Company), and ADAM R. CRAIG (Executive). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Severance Agreement (as defined below).

Executive Severance Benefits Agreement (June 30th, 2011)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is made and entered into effective as of January 3, 2011 (the Commencement Date), between Guitar Center, Inc., a Delaware corporation (the Company), and Soren Mills (the Executive).

Executive Severance Benefits Agreement (June 30th, 2011)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is made and entered into effective as of April , 2010 (the Commencement Date), between Guitar Center, Inc., a Delaware corporation (the Company), and Erick Mason (the Executive).

Executive Severance Benefits Agreement (February 5th, 2010)

This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the Agreement) is entered into this day of , (the Effective Date), between (Executive) and SYMMETRICOM, INC. (the Company). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events.

Amended and Restated Executive Severance Benefits Agreement (April 3rd, 2009)

This Amended and Restated Executive Severance Benefits Agreement (the "Agreement") is entered into this 23rd day of December, 2008 (the "Effective Date"), between Steve Ketchum ("Executive") and Sunesis Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.

Second Amended and Restated Executive Severance Benefits Agreement (April 3rd, 2009)

This Second Amended and Restated Executive Severance Benefits Agreement (the "Agreement") is entered into this 24th day of December, 2008 (the "Effective Date"), between Valerie L. Pierce ("Executive") and Sunesis Pharmaceuticals, Inc. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.